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ABSTRACT  
 
Thalassotalic acids A-C and thalassotalamides A and B are new N-acyl dehydrotyrosine 
derivatives produced by Thalassotalea sp.  PP2-459, a Gram-negative bacterium isolated from a 
marine bivalve aquaculture facility.  The structures were elucidated via a combination of 
spectroscopic analyses emphasizing two-dimensional NMR and high-resolution mass 
spectrometric data. Thalassotalic acid A (1) displays in vitro inhibition of the enzyme tyrosinase 
with an IC50 value (130 µM) that compares favorably to the commercially-used control 
compounds kojic acid (46 µM) and arbutin (100 µM). These are the first natural products 
reported from a bacterium belonging to the genus Thalassotalea. 
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Marine bacteria continue to be a highly productive source of new natural products with 
169 new compounds reported in 2013 alone.1 While marine Gram-positive bacteria, especially 
actinomycetes, have garnered the most attention to date, genome mining and isolation-driven 
discovery efforts have raised awareness for the biosynthetic potential of marine Gram-negative 
bacteria (GNB).2, 3  Recognition that marine GNB produce such molecules as the didemnins,4 
and quite likely the bryostatins,5 highlights the potential for discovery of molecules with 
biomedical value. The marine γ-proteobacteria have been a particularly productive taxonomic 
group of GNB for natural product studies, yielding notable antibiotics such as andrimid and the 
moiramides, as well as the signaling molecule AI-2.6, 7  These studies and others portend the 
future success of discovery efforts aimed at marine GNB.  
Thalassotalea is a new Gram-negative, aerobic, γ-proteobacteria genus.8  This genus was 
first characterized in 2014 following reclassification of members of the genus Thalassomonas.8 
There have been only 10 species of Thalassotalea discussed in the literature and they have been 
primarily studied for their agarolytic properties, commensalism with marine animals, and 
pathogenic contribution to coral diseases.8-13 To date, there have been no published secondary 
metabolite studies on this genus.8-11 
The enzyme tyrosinase is responsible for three transformations in the conversion of 
tyrosine to melanin, which is responsible for pigmentation of skin, hair, and eyes.14  It 
specifically catalyzes the conversion of L-tyrosine to 3,4-dihydroxyphenylalanine (L-DOPA), L-
DOPA to dopaquinone, and 5,6-dihydroxyindole (DHI) to indole-quinone.14 Because of 
tyrosinase’s role in pigmentary diseases such as albinism and melasma, as well as cosmetic 
relevance to increase or decrease skin or hair color and pigmentation, compounds that can 
modulate tyrosinase have potential therapeutic and cosmetic applications.15  Additionally, 
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tyrosinase is responsible for enzymatic browning of foods and inhibition of this process could 
lead to improved agricultural lifespans and nutrition.16  
In this paper, we report new N-acyl dehydrotyrosine derivatives (1-5) produced during 
laboratory cultivation of Thalassotalea sp. PP2-459, formerly classified as Thalassomonas sp. 
PP2-459, a strain isolated from a carpet-shell clam (Ruditapes decussata) harvested in a bivalve 
hatchery located in Galicia (NW Spain).17  PP2-459 was previously determined to have quorum 
quenching ability against key bivalve aquaculture pathogens, including Vibrio anguillarum.17  
Hence, PP2-459 has been proposed as a candidate for probiotic applications in aquaculture.  Due 
to structural similarity with known tyrosinase inhibitors such as N-acylated tyrosines, 1-5 were 
evaluated for their inhibition of the tyrosinase enzyme.   
 Thalassotalea PP2-459 was cultured in YP seawater medium at 25 °C shaking and 200 
rpm for two days.  The cultures were centrifuged at 10,000 g for 10 min to substantially remove 
the cells, and the resulting supernatants were extracted with EtOAc.  Purification efforts using 
reversed-phase (C18) chromatography methods yielded new compounds 1-5.   
Thalassotalic acid A (1) was isolated as a light brown powder.  The molecular formula 
was determined to be C19H27NO4 using HRESIMS (m/z 332.1866 [M-H]-), indicating seven 
degrees of unsaturation.  The presence of a decanoyl chain was supported by 1H NMR 
resonances at δH 0.90 (t, 3H, H-10'), 1.29-1.31 (m, 12H, H-4'-H-9'), 1.59 (m, 2H, H-3'), and 2.28 
(t, 2H, H-2') that comprised a spin system in the COSY spectrum (Table 1). 13C NMR resonances 
at δC 172.0 (C-1') and 166.7 (C-1) indicated the presence of two carbonyl carbons, the former 
belonging to the decanoyl chain based on HMBC correlations from H-2′ and H-3′.  In the 
aromatic region, two doublets at δH 6.80 (H-6, J = 8.7 Hz) and 7.51 (H-5, J = 8.7 Hz) provided 
evidence for a para-substituted benzene ring.  A HSQC correlation assigned a sharp singlet at δH 
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7.22 (H-3) as an olefinic methine attached to carbon at δC 132.2.  HMBC correlations from H-5 
to C-3 and H-3 to C-5 indicated that the C-3 methine was the benzylic position of the para-
substituted aromatic ring. Consideration of the molecular formula and further HMBC 
correlations from the C-2-NH to C-1, C-2, and C-3, as well as correlations from H-3 to C-1 and 
C-2, established the α-β unsaturated tyrosine (Figure 1).  The (Z)-configuration of the double 
bond was determined based on NOE correlations shown in Figure 1.  TOF-MS/MS experiments 
further corroborated the proposed structure. Product ions were observed indicating the loss of 
CO2H (m/z 288.2, [M-45]), the decanoyl chain (m/z 178.0, [M-155]), and both the carboxylic 
acid and the acyl chain (m/z 134.0, [M-199]).  
The structure of thalassotalic acid B (2) was determined by comparison to spectroscopic 
data of 1.  An [M-H]- ion at m/z 332.1872 indicated the same molecular formula as 1: 
C19H27NO4.  A key difference in the 1H NMR spectrum was the presence of a sharp doublet at δH 
0.90 that integrated for six protons, suggesting a terminal branch in the aliphatic chain.  Analysis 
of the HSQC spectrum revealed an aliphatic methine at δH 1.55 and δC 27.4, whose 1H NMR 
resonance coupled to the C-8' methyl groups in the COSY spectrum, thus confirming the 
terminal (CH3)2CH- group. The remaining structure was determined to be identical to 1 based on 
comparison of 13C and 2D NMR data and TOF-MS/MS evidence.     
Thalassotalic acid C (3) displayed a HRESIMS ion (m/z 318.1699 [M-H]-) consistent 
with a molecular formula of C18H25NO4, which is one CH2 unit fewer than 1 and 2.  Comparison 
of 1H and 13C NMR data with 1 and 2 revealed that 3 shared the same core tyrosine structure, but 
incorporated an unbranched chain containing one fewer methylene unit than 1.  Thus, 3 was 
determined to be the nonanoyl analog of 1.  TOF-MS/MS further corroborated this structure with 
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the characteristic losses of CO2H (m/z 274.2, [M-45]), the nonanoyl chain (m/z 178.1, [M-141]), 
and both the carboxylic acid and the acyl chain (m/z 134.1 [M-185]). 
 Thalassotalamide A (4) was isolated as an amorphous brown powder.  HRESIMS 
indicated that the molecular formula was C19H28N2O3 based on an [M-H]- ion (m/z 331.2021).  
Thus, 4 had an additional NH and one less O than 1. Examination of the 1H NMR spectrum of 4 
indicated strong similarity to 1 based on resonances attributed to the p-substituted benzene ring 
(two doublets each integrating as 2H  at δH 6.78 and 7.42) and unbranched aliphatic chain.  The 
outstanding difference was two broad singlets at δH 7.05 and 7.28, indicating that 4 was likely the 
amide analog of 1.  TOF-MS/MS confirmed this suspicion as fragment ions of m/z 288.2 [M-44] 
and m/z 134.1 [M-198] were observed, indicating that the α-β unsaturated carbonyl was an amide 
and not a carboxylic acid.  Analysis of 13C and 2D NMR and further confirmed the structure of 4.   
 The structure of thalassotalamide B (5) was elucidated by comparison to spectroscopic 
data of 2 and 4.  HRESIMS indicated that the molecular formula of 5 was the same as 4 
(C19H28N2O3) based on an [M-H]- ion (m/z 331.2015).  In the 1H NMR spectrum, a doublet at δH 
0.89 integrating 6H suggested that 5 had the same branched aliphatic chain as 2.  Comparison of 
13C NMR data from the aliphatic chain of 2 to 5 confirmed they had the same 8-methyl nonanoyl 
aliphatic chain.  Comparison of the remaining 13C NMR data to those of 4, as well as the 
prominent loss of the amide in TOF-MS/MS (m/z 288.2), indicated that 5 was the amide 
derivative of 2.   
 N-acyl tyrosines have previously been studied for their effects on pigmentation of skin 
and hair.18-20 These compounds have been implicated in both increasing and decreasing 
pigmentation.18-20  Because of the similarity in structure to N-acyl tyrosines, we evaluated 
compounds 1-5 for their effects on tyrosinase enzyme activity compared to the positive controls 
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arbutin (6) and kojic acid (7) that have been widely used in skin whitening products.21, 22  
Compounds 1, 2, and 3 exhibited tyrosinase enzyme inhibition with IC50 values of 130 ± 10 µM, 
470 ± 10 µM, and 280 ± 10 µM, respectively.  The IC50 value for 1 compared favorably to the 6 
(100 ± 10 µM), but was less effective than 7 (IC50 = 46 ± 2 µM).  Compounds 4 and 5 were 
inactive at the maximum tested concentration (1 mM).  These data support the requirement for a 
carboxylic acid and straight aliphatic chain for increasing enzyme inhibition within this structural 
class of tyrosinase inhibitors.  While these N-acyl dehydrotyrosine compounds are not as potent 
as 6 or 7, 1 displays comparable tyrosinase inhibition and could be useful as a whitening agent or 
as an agricultural additive to prevent the browning of foods. 16  
N-acyl derivatives of amino acids, including tyrosine, have been previously produced via 
heterologous expression of environmental DNA in Escherichia coli.  These molecules are 
products of N-acyl amino acid synthases, which have been observed as single genes or as part of 
more complex biosynthetic sequences.23, 24While the compounds discussed here are structurally 
similar, the dehydrogenation across the α-β carbons of the tyrosine, the terminal amide functional 
group in 4 and 5, and the branched acyl chains in 2 and 5 represent biosynthetic variations not 
present in heterologously produced N-acyl tyrosines.24  Additionally, these are the first natural 
products reported from a bacterium belonging to the genus Thalassotalea. 
 
EXPERIMENTAL SECTION 
General Experimental Procedures: All chemical reagents and solvents were purchased from 
Sigma-Aldrich and acquired via Wilkem Scientific.  UV spectra were acquired with a DU 800 
UV/Vis Spectrophotometer (Beckman Coulter).  IR spectra were acquired with a Nicolet 380 
FT-IR (Thermo Electron Corporation).  NMR experiments were conducted using an Agilent 
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NMRS 500 MHz spectrometer with (CD3)2SO as the solvent (referenced to residual DMSO at δH 
2.54 and δC 39.5) at 25 °C.  Electrospray ionization mass spectra (ESIMS) were acquired using 
an AB Sciex TripleTOF 4600 spectrometer in the negative ion mode.  Flash chromatography was 
completed with a Combiflash Rf200 equipped with an 86 g C18 RediSepRf High Performance 
Gold column (Teledyne ISCO). HPLC experiments were performed on a Hitachi Elite LaChrom 
system equipped with a diode array detector (DAD) model L-2450, pump L-2130, and 
autosampler L-2200.  Semi-preparative HPLC experiments were completed with a Waters 
XBridge Prep C18 5 µm, 10 × 250 mm column.  
Bacterial Strain and Culture Conditions:  The bacteria strain (PP2-459) was isolated from a 
bivalve hatchery in Galicia, Spain and identified as a Thalassotalea sp. based on 16S rRNA 
sequence comparison (European Nucleotide Archive; accession number LN898116).17 It has 
been deposited in the Spanish Type Culture Collection (CECT) under restricted access.  Cultures 
were maintained in YP seawater medium (1 g yeast extract, 5 g peptone, 22.5 g Instant Ocean 
(Spectrum Brands) per liter of deionized water) at 25 °C and shaking at 200 rpm.   
Extraction and Isolation: A total of 17 L of bacterial cultures were cultivated and centrifuged at 
10,000 g for 10 min to remove cells.  The culture supernatants were extracted twice with equal 
volumes of EtOAc.  The resultant organic layer was concentrated in vacuo to generate a total 
extract of 1.5 g.   
 The extract was adsorbed onto C18 resin (BAKERBOND Octadecyl (C18) 40 µm Prep LC 
Packing) and separated by reversed-phase flash chromatography.  A linear gradient of 10 - 100% 
MeOH in H2O, each solvent modified with 0.1% formic acid (FA), afforded five fractions.  
Fraction 4 (135.6 mg) was further purified by reversed-phase C18 semi-preparative HPLC (25 
min linear gradient from 40 - 78% MeOH in H2O (0.1% FA) to yield five pure compounds: 1 
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(28.3 mg, tR = 17.9 min), 2 (10.1 mg, tR = 16.9 min), 3 (7.8 mg, tR = 13.8 min), 4 (2.3 mg, tR = 
16.0 min), and 5 (2.2 mg, tR = 15.1 min). 
 Thalassotalic acid A (1): off-white amorphous powder; UV (MeOH) λmax (log ε) 201 
(4.16) 298 (3.99) nm; IR (ZnSe) υmax 3308, 3067 (br), 2917, 2850, 1688, 1656, 1601, 1584, 
1271, 1167 cm-1; 1H and 13C NMR data, Table 1; HRESIMS m/z 332.1866 [M-H]- (calcd for 
C19H26NO4, 332.1867).  
 Thalassotalic acid B (2): brown amorphous powder; UV (MeOH) λmax (log ε) 201 (4.12) 
299 (4.03) nm; IR (ZnSe) υmax 3326, 3118 (br), 2925, 2853, 1688, 1656, 1601, 1584, 1270, 1168 
cm-1; 1H and 13C NMR data, Table 1; HRESIMS m/z 332.1872 [M-H]- (calcd for C19H26NO4, 
332.1867).  
 Thalassotalic acid C (3): brown amorphous powder; UV (MeOH) λmax (log ε) 202 (4.27) 
299 (4.37) nm; IR (ZnSe) υmax 3317, 3067 (br), 2922, 2852, 1692, 1655, 1601, 1584, 1270, 1168 
cm-1; 1H and 13C NMR data, Table 1; HRESIMS m/z 318.1699 [M-H]- (calcd for C18H24NO4, 
318.1711). 
 Thalassotalamide A (4): brown amorphous powder; 1H and 13C NMR data, Table 1; 
HRESIMS m/z 331.2021 [M-H]- (calcd for C19H27N2O3, 331.2027). 
 Thalassotalamide B (5): brown amorphous powder; UV (MeOH) λmax (log ε) 200 (4.26) 
210 (4.19) 272 (3.59) nm; IR (ZnSe) υmax 3726, 3624, 3321, 2925, 2854, 1665, 1578, 1137 cm-1; 
1H and 13C NMR data, Table 1; HRESIMS m/z 331.2015 [M-H]- (calcd for C19H27N2O3, 
331.2027). 
 
Tyrosinase Inhibition Assay: Inhibitory effects of compounds 1-5 on mushroom tyrosinase 
were evaluated spectrophotometrically using L-tyrosine as a substrate according to our 
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previously published method with minor modification.21  Tyrosinase inhibition assays were 
performed in 96-well microplate format using a SpectraMax M2 microplate reader (Molecular 
Devices).  Briefly, compounds were dissolved at various concentrations in 10% MeOH in 
phosphate buffer solution (PBS; 0.1 M, pH 6.8).  Each well contained 40 µL of sample with 80 
µL of PBS, 40 µL of tyrosinase (100 units/mL), and 40 µL L-tyrosine (2.5 mM). The mixture 
was incubated for 30 min at 37 °C, and absorbance was measured at 490 nm. Each sample was 
accompanied by a blank containing all components except L-tyrosine. Arbutin and kojic acid 
were used as positive controls.  The results were compared with a control consisting of 10% 
MeOH in place of the test compounds. Experiments were completed in triplicate for each 
compound. The percentage of tyrosinase inhibition was calculated as: [(ΔAcontrol − ΔAsample)/ 
ΔAcontrol] × 100.  
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Table 1. NMR Spectroscopic data (1H 500 MHz, 13C 125 MHz, DMSO-d6) for Thalassotalic acids A-C (1-3) and Thalassotalamides A 
(4) and B (5). 
	  
 
Thalassotalic acid A (1) Thalassotalic acid B (2) Thalassotalic acid C (3) Thalassotalamide A (4) Thalassotalamide B (5) 
position δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz) 
1 166.7, C   166.7, C   166.8, C   167.2, C   167.2, C   
1-OH/NH2  
12.35, br s 
 
12.23, br s 
 
12.26, br s 
 
7.28/7.05, br s 
 
7.28/7.05, br s 
2 124.2, C 
 
124.3, C  
 
124.5, C  
 
127.0, C 
 
127.0, C  
 
2-NH 
 
9.23, s 
 
9.22, s 
 
9.20, s 
 
9.18, s 
 
9.19, s 
3 132.2, CH 7.22, s 132.0, CH  7.22, s 131.7,a CH  7.21, s 128.6, CH 7.06, s  128.6, CH  7.06, s 
4 124.7, C  
 
124.7, C  
 
124.8, C  
 
125.0, C  
 
125.0, C  
 
5 131.7, CH  7.51, d (8.7) 131.7, CH  7.51, d (8.6) 131.7,a CH  7.50, d (8.5) 131.2, CH  7.42, d (8.7) 131.2, CH  7.42, d (8.5) 
6 115.3, CH  6.80, d (8.7) 115.3, CH  6.80, d (8.5) 115.3, CH  6.79, d (8.5) 115.2, CH  6.78, d (8.7) 115.2, CH  6.78, d (8.5) 
7 158.5, C   158.5, C   158.5, C   158.0, C   158.1, C   
7-OH 
 
9.94, br s 
 
10.02, br s 
 
10.03, br s 
 
10.00, br s 
 
10.03, br s 
1' 172.0, C  
 
171.9, C 
 
171.8, C  
 
172.0, C  
 
172.0, C 
 
2' 35.1, CH2  2.28, t (7.2) 35.2, CH2   2.28, t (7.4) 35.2, CH2   2.28, t (7.2) 35.2, CH2   2.32, t (7.5) 35.2, CH2   2.32, t (7.5) 
3' 25.0, CH2 1.59, m 25.0, CH2   1.59, m 25.0, CH2   1.59, m 24.7, CH2   1.58, m 24.7, CH2   1.58, m 
4' 
28.6-29.0, 
CH2 
1.31, ma 28.7, CH2   1.34, ma 
28.6-28.8, 
CH2   
1.31, ma 28.7-28.9, CH2   1.31, ma 28.8, CH2   1.32, ma 
5' 28.6-29.0, 
CH2  
1.31, ma 29.1, CH2   1.30, ma 
28.6-28.8, 
CH2   
1.31, ma 28.7-28.9, CH2   1.31, ma 29.1, CH2   1.28, ma 
6' 
28.6-29.0, 
CH2  
1.31, ma 26.7, CH2   1.30, ma 
28.6-28.8, 
CH2   
1.31, ma 28.7-28.9, CH2   1.31, ma 26.7, CH2   1.30, ma 
7' 
28.6-29.0, 
CH2  
1.31, ma 38.4, CH2   1.19, m 31.2, CH2   1.30, ma 28.7-28.9, CH2   1.31, ma 38.4, CH2   1.19, m 
8' 31.3, CH2  1.29, ma 27.4, CH2   1.55, m 22.1, CH2   1.32, ma 31.3, CH2   1.29, ma 27.4, CH2   1.55, m 
9' 22.1, CH2   1.30, ma 22.5, CH3 0.90, d (6.6) 13.9, CH3  0.90, t (7.0) 22.1, CH2   1.30, ma 22.5, CH3  0.89, d (6.5) 
10' 13.9, CH3  0.90, t (7.0)     
13.9, CH3 0.90, t (7.0)   
aOverlapped signal     
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Figure 1. Key COSY, HMBC, and NOESY correlations for thalassotalic acid A (1).  
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